Table 1.

Patients’ baseline demographics in the entire cohort (left column) and in ALK and ROS1-patients separately (middle and right column).

	All patients (n = 52)	ALK-positive (n = 37)	ROS1-positive (n = 15)
Age, years (range)	57 (32–81)	58 (32–70)	56 (36–81)
Sex, n (%)
Female	28 (53.8)	18 (48.6)	10 (66.7)
Male	24 (46.2)	19 (51.4)	5 (33.3)
Smoking history, n (%)
Current smoker	4 (7.7)	3 (8.1)	1 (6.7)
Former smoker	14 (26.9)	10 (27.0)	4 (27.6)
Never smoker	32 (61.5)	22 (59.4)	10 (66.7)
Missing data	2 (3.8)	2 (5.4)
Performance Status at primary diagnosis, n (%)
0	31 (59.6)	24 (64.9)	7 (46.7)
1	16 (30.8)	10 (27.0)	6 (40.0)
2	1 (1.9)	1 (2.7)
missing data	4 (7.7)	2 (5.4)	2 (13.3)
Histology, n (%)
Adenocarcinoma	51 (98.1)	37 (100.0)	14 (93.3)
Adenosquamous carcinoma	1 (1.9)		1 (6.7)
Brain metastases at primary diagnosis, n (%)
Yes	13 (25.0)	11 (29.7)	2 (13.3)
No	38 (73.1)	25 (67.7)	13 (86.7)
Missing data	1 (1.9)	1 (2.7)
Stage at primary diagnosis
III	6 (11.5)	4 (10.8)	2 (13.3)
IV	46 (88.5)	33 (89.2)	13 (86.7)
Prior systemic therapies, n (range)	4 (1–9)	5 (2–9)	3 (1–5)
Prior targeted therapies, n (range)	3 (1–4)	3 (1–4)	1 (1–2)
Crizotinib	50 (96.2)	35 (94.6)	15 (100.0)
Ceritinib	37 (71.2)	33 (89.2)	4 (26.7)
Alectinib	34 (65.4)	34 (91.9)
Brigatinib	13 (25.0)	13 (35.1)
Performance Status at enrolment, n (%)
0	12 (23.1)	8 (21.6)	4 (26.7)
1	27 (51.9)	19 (51.4)	8 (53.3)
2	9 (17.3)	7 (18.9)	2 (13.3)
3	2 (3.8)	2 (5.4)
4	2 (3.8)	1 (2.7)	1 (6.7)
Brain metastases at enrolment, n (%)
Yes	36 (69.2)	26 (70.3)	10 (66.7)
No	16 (30.8)	11 (29.7)	5 (33.3)
Leptomeningeal disease at enrolment, n (%)
Yes	9 (25.0)	6 (23.1)	3 (30.0)
No	27 (75.0)	20 (76.9)	7 (70.0)